View Our Newest Version Here

2014 Tennessee Code
Title 39 - Criminal Offenses
Chapter 17 - Offenses Against Public Health, Safety and Welfare
Part 4 - Drugs
§ 39-17-410 - Controlled substances in Schedule III.

TN Code § 39-17-410 (2014) What's This?

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) Stimulants, unless specifically excepted or unless listed in another schedule, means any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under 21 CFR 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;

(2) Benzphetamine;

(3) Chlorphentermine;

(4) Clortermine; or

(5) Phendimetrazine.

(c) Depressants, unless specifically excepted or unless listed in another schedule, means any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

(A) Amobarbital;

(B) Secobarbital;

(C) Pentobarbital;

or any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule;

(2) Any suppository dosage form containing:

(A) Amobarbital;

(B) Secobarbital;

(C) Pentobarbital;

or any salt of any of these drugs and approved by the United States food and drug administration for marketing only as a suppository;

(3) Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof;

(A) Aprobarbital;

(B) Butabarbital (secbutabarbital);

(C) Butalbital;

(D) Butobarbital (butethal);

(E) Talbutal;

(F) Thiamylal;

(G) Thiopental; or

(H) Vinbarbital;

(4) Chlorhexadol;

(5) Embutramide;

(6) Gamma hydroxybutyric acid preparations. Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under § 505 of the federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 355;

(7) Ketamine, its salts, isomers, and salts

Other name: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

(8) Lysergic acid;

(9) Lysergic acid amide;

(10) Methyprylon;

(11) Sulfondiethylmethane;

(12) Sulfonethylmethane;

(13) Sulfonmethane; or

(14) Tiletamine and zolazepam or any salt of tiletamine or zolazepam:

(A) Other name for a tiletamine-zolazepam combination product: Telazol(R);

(B) Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; and

(C) Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one; flupyrazapon.

(d) Nalorphine.

(e) Narcotic drugs, unless specifically excepted or unless listed in another schedule, means:

(1) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(C) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(D) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts;

(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts;

(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active nonnarcotic ingredients in recognized therapeutic amounts;

(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than twenty-five (25) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts:

(A) Buprenorphine.

(f) Anabolic steroids, unless specifically excepted or unless listed in another schedule, means any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:

(1) Anabolic steroids:

(A) 3[beta],17-dihydroxy-5a-androstane;

(B) 3[alpha],17[beta]-dihydroxy-5a-androstane;

(C) 5[alpha]-androstan-3,17-dione;

(D) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

(E) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

(F) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

(G) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

(H) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione);

(I) 4-androstenedione (androst-4-en-3,17-dione);

(J) 5-androstenedione (androst-5-en-3,17-dione);

(K) Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

(L) Boldenone (17[beta]-hydroxyandrost-1,4,-diene-3-one);

(M) Boldione (androsta-1,4-diene-3,17-dione);

(N) Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

(O) Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one)

Other name: Chlorotestosterone;

(P) Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methyl-androst-1,4-dien-3-one);

(Q) [Delta]1-dihydrotestosterone (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);

(R) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one)

Other name: Stanolone;

(S) Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]- androstan-3-one);

(T) Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);

(U) Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);

(V) Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);

(W) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan);

(X) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;

(Y) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one);

(Z) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-4-en-3- one);

(AA) Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);

(BB) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3-one);

(CC) Mesterolone (1[alpha]methyl-17[beta]-hydroxy-[5[alpha]]-androstan-3-one);

(DD) Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);

(EE) Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);

(FF) Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);

(GG) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane;

(HH) 17[alpha]-methyl-3[alpha], 17[beta]-dihydroxy-5a-androstane;

(II) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxyandrost-4-ene;

(JJ) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);

(KK) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);

(LL) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);

(MM) Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);

(NN) Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);

(OO) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-1-testosterone');

(PP) Nandrolone (17[beta]-hydroxyestr-4-en-3-one);

(QQ) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene);

(RR) 19-nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene);

(SS) 19-nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene);

(TT) 19-nor-5-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene);

(UU) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

(VV) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(WW) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(XX) Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);

(YY) Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);

(ZZ) Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);

(AAA) Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);

(BBB) Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-[5[alpha]]-androstan-3-one);

(CCC) Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);

(DDD) Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]- hydroxy-[5[alpha]]-androstan-3-one);

(EEE) Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]- androst-2-eno[3,2-c]-pyrazole);

(FFF) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one);

(GGG) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

(HHH) Testosterone (17[beta]-hydroxyandrost-4-en-3-one);

(III) Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);

(JJJ) Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); or

(KKK) Methandrostenolone;

(2) Any salt, ester, or ether of a drug or substance described in this subsection (f). Except such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the secretary of health and human services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection (f);

(3) Anabolic steroids with a combination of estrogens intended for administration to hormone deficient women are exempt from this rule unless such steroids are prescribed, dispensed, or distributed to women who are not hormone deficient.

(g) Hallucinogenic substances.

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product.

Other names: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol] or (-)-delta-9-(trans)-tetrahydrocannabinol].

Disclaimer: These codes may not be the most recent version. Tennessee may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.